Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WUNGKI PARK

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1457617771
CMS profile
2780883
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$4,450.57

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,268.00 1
Travel and Lodging $1,050.69 3
Food and Beverage $131.88 2

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Regeneron Pharmaceuticals, Inc. $4,450.57 6

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WUNGKI PARK

NPI 1457617771 · CMS profile ID 2780883

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1457617771?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WUNGKI PARK, NPI 1457617771, CMS profile ID 2780883. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457617771?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). WUNGKI PARK, NPI 1457617771, CMS profile ID 2780883. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457617771?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
WUNGKI PARK, NPI 1457617771, CMS profile ID 2780883, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1457617771?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $4,450.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Pharmaceuticals, Inc. $3,268.0012/06/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114403281 CMS
Regeneron Pharmaceuticals, Inc. $911.6812/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114403283 CMS
Regeneron Pharmaceuticals, Inc. $113.1412/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114403285 CMS
Regeneron Pharmaceuticals, Inc. $25.8712/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114403287 CMS
Regeneron Pharmaceuticals, Inc. $46.3012/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114403289 CMS
Regeneron Pharmaceuticals, Inc. $85.5810/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114403279 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $126.78 1
PY2023 $110.78 1
PY2024 $4,450.57 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $5,772,986.59 668
PY2024 Principal investigator $4,393,777.13 199
PY2023 Principal investigator $5,266,392.43 164
PY2022 Principal investigator $5,283,436.36 4
PY2021 Principal investigator $3,810,346.16 3
PY2020 Principal investigator $930,010.08 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

668 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $2,184,701.20 12/31/2025 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 2 Trial to Evaluate the Safety and Antitumor Activity of Pembrolizumab and OLApaRib (POLAR) for Individuals with Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency No dispute reported 06/30/2026 1232932235
Principal investigator 1 Astellas Pharma Inc $4,091.43 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363225
Principal investigator 1 Astellas Pharma Inc $5,910.49 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363227
Principal investigator 1 Astellas Pharma Inc $3,640.71 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363229
Principal investigator 1 Astellas Pharma Inc $3,607.04 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363231
Principal investigator 1 Astellas Pharma Inc $3,607.04 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363233
Principal investigator 1 Astellas Pharma Inc $3,640.71 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363235
Principal investigator 1 Astellas Pharma Inc $3,607.04 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363237
Principal investigator 1 Astellas Pharma Inc $3,640.71 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363239
Principal investigator 1 Astellas Pharma Inc $3,607.04 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363241
Principal investigator 1 Astellas Pharma Inc $1,823.08 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363243
Principal investigator 1 Astellas Pharma Inc $4,091.43 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363245
Principal investigator 1 Astellas Pharma Inc $1,823.08 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363247
Principal investigator 1 Astellas Pharma Inc $1,823.08 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363249
Principal investigator 1 Astellas Pharma Inc $5,910.49 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363251
Principal investigator 1 Astellas Pharma Inc $3,607.04 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363253
Principal investigator 1 Astellas Pharma Inc $4,018.71 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363255
Principal investigator 1 Astellas Pharma Inc $5,390.93 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363257
Principal investigator 1 Astellas Pharma Inc $1,823.08 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363259
Principal investigator 1 Astellas Pharma Inc $1,823.08 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363261
Principal investigator 1 Astellas Pharma Inc $3,607.04 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363263
Principal investigator 1 Astellas Pharma Inc $3,607.04 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363265
Principal investigator 1 Astellas Pharma Inc $4,598.29 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363267
Principal investigator 1 Astellas Pharma Inc $4,091.43 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363269
Principal investigator 1 Astellas Pharma Inc $3,607.04 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363271
Principal investigator 1 Astellas Pharma Inc $5,390.93 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363273
Principal investigator 1 Astellas Pharma Inc $3,607.04 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363275
Principal investigator 1 Astellas Pharma Inc $3,607.04 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363277
Principal investigator 1 Astellas Pharma Inc $3,640.71 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363279
Principal investigator 1 Astellas Pharma Inc $4,091.43 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363281
Principal investigator 1 Astellas Pharma Inc $4,018.71 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363283
Principal investigator 1 Astellas Pharma Inc $4,061.91 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363285
Principal investigator 1 Astellas Pharma Inc $4,061.91 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363287
Principal investigator 1 Astellas Pharma Inc $3,640.71 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363289
Principal investigator 1 Astellas Pharma Inc $2,585.75 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363291
Principal investigator 1 Astellas Pharma Inc $4,061.91 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363293
Principal investigator 1 Astellas Pharma Inc $4,018.71 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363295
Principal investigator 1 Astellas Pharma Inc $7,032.93 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363297
Principal investigator 1 Astellas Pharma Inc $3,607.04 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363299
Principal investigator 1 Astellas Pharma Inc $4,018.71 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363301
Principal investigator 1 Astellas Pharma Inc $4,598.29 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363303
Principal investigator 1 Astellas Pharma Inc $4,061.91 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363305
Principal investigator 1 Astellas Pharma Inc $3,640.71 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363307
Principal investigator 1 Astellas Pharma Inc $4,091.43 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363309
Principal investigator 1 Astellas Pharma Inc $4,091.43 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363311
Principal investigator 1 Astellas Pharma Inc $3,640.71 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363313
Principal investigator 1 Astellas Pharma Inc $7,032.93 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363315
Principal investigator 1 Astellas Pharma Inc $7,032.93 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363317
Principal investigator 1 Astellas Pharma Inc $4,091.43 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363319
Principal investigator 1 Astellas Pharma Inc $4,091.43 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363321
Principal investigator 1 Astellas Pharma Inc $3,640.71 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363323
Principal investigator 1 Astellas Pharma Inc $2,585.75 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363325
Principal investigator 1 Astellas Pharma Inc $3,640.71 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363327
Principal investigator 1 Astellas Pharma Inc $3,640.71 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363329
Principal investigator 1 Astellas Pharma Inc $3,640.71 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363331
Principal investigator 1 Astellas Pharma Inc $4,091.43 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363333
Principal investigator 1 Astellas Pharma Inc $1,823.08 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363335
Principal investigator 1 Astellas Pharma Inc $7,032.93 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363337
Principal investigator 1 Astellas Pharma Inc $1,823.08 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363339
Principal investigator 1 Astellas Pharma Inc $4,061.91 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363341
Principal investigator 1 Astellas Pharma Inc $4,091.43 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363343
Principal investigator 1 Astellas Pharma Inc $1,823.08 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363345
Principal investigator 1 Astellas Pharma Inc $1,823.08 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363347
Principal investigator 1 Astellas Pharma Inc $4,061.91 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363349
Principal investigator 1 Astellas Pharma Inc $3,640.71 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363351
Principal investigator 1 Astellas Pharma Inc $4,061.91 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363353
Principal investigator 1 Astellas Pharma Inc $2,861.15 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363355
Principal investigator 1 Astellas Pharma Inc $2,861.15 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363357
Principal investigator 1 Astellas Pharma Inc $3,640.71 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363359
Principal investigator 1 Astellas Pharma Inc $1,823.08 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363361
Principal investigator 1 Astellas Pharma Inc $4,091.43 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363363
Principal investigator 1 Astellas Pharma Inc $1,823.08 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363365
Principal investigator 1 Astellas Pharma Inc $4,018.71 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363367
Principal investigator 1 Astellas Pharma Inc $1,823.08 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363369
Principal investigator 1 Astellas Pharma Inc $5,390.93 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363371
Principal investigator 1 Astellas Pharma Inc $4,061.91 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363373
Principal investigator 1 Astellas Pharma Inc $3,640.71 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363375
Principal investigator 1 Astellas Pharma Inc $4,598.29 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363377
Principal investigator 1 Astellas Pharma Inc $1,823.08 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363379
Principal investigator 1 Astellas Pharma Inc $4,598.29 11/27/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363381
Principal investigator 1 Astellas Pharma Global Development $464.00 11/25/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Open-label Study to Assess the Safety and Tolerability of Zolbetuximab (IMAB362) in Combination With Chemotherapy (mFOLFIRINOX) in Participants With CLDN18.2 Positive Metastatic Pancreatic Adenocarcinoma No dispute reported 06/30/2026 1234183567
Principal investigator 1 Merck Sharp & Dohme LLC $199,999.79 10/20/2025 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 2 Trial to Evaluate the Safety and Antitumor Activity of Pembrolizumab and OLApaRib (POLAR) for Individuals with Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency No dispute reported 06/30/2026 1232932049
Principal investigator 1 Astellas Pharma Inc $4,598.29 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363095
Principal investigator 1 Astellas Pharma Inc $3,607.04 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363097
Principal investigator 1 Astellas Pharma Inc $5,910.49 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363099
Principal investigator 1 Astellas Pharma Inc $1,823.08 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363101
Principal investigator 1 Astellas Pharma Inc $1,823.08 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363103
Principal investigator 1 Astellas Pharma Inc $1,823.08 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363105
Principal investigator 1 Astellas Pharma Inc $4,091.79 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363107
Principal investigator 1 Astellas Pharma Inc $4,598.29 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363109
Principal investigator 1 Astellas Pharma Inc $3,607.04 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363111
Principal investigator 1 Astellas Pharma Inc $3,640.71 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363113
Principal investigator 1 Astellas Pharma Inc $4,018.71 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363115
Principal investigator 1 Astellas Pharma Inc $4,061.91 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363117
Principal investigator 1 Astellas Pharma Inc $3,607.04 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363119
Principal investigator 1 Astellas Pharma Inc $3,640.71 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363121
Principal investigator 1 Astellas Pharma Inc $1,823.08 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363123
Principal investigator 1 Astellas Pharma Inc $1,823.08 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363125
Principal investigator 1 Astellas Pharma Inc $3,607.04 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363127
Principal investigator 1 Astellas Pharma Inc $3,640.71 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363129
Principal investigator 1 Astellas Pharma Inc $3,640.71 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363131
Principal investigator 1 Astellas Pharma Inc $1,823.08 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363133
Principal investigator 1 Astellas Pharma Inc $4,061.91 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363135
Principal investigator 1 Astellas Pharma Inc $3,607.04 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363137
Principal investigator 1 Astellas Pharma Inc $4,598.29 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363139
Principal investigator 1 Astellas Pharma Inc $3,607.04 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363141
Principal investigator 1 Astellas Pharma Inc $4,061.91 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363143
Principal investigator 1 Astellas Pharma Inc $4,598.29 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363145
Principal investigator 1 Astellas Pharma Inc $1,823.08 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363147
Principal investigator 1 Astellas Pharma Inc $5,390.93 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363149
Principal investigator 1 Astellas Pharma Inc $1,823.08 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363151
Principal investigator 1 Astellas Pharma Inc $4,018.71 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363153
Principal investigator 1 Astellas Pharma Inc $4,018.71 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363155
Principal investigator 1 Astellas Pharma Inc $3,640.71 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363157
Principal investigator 1 Astellas Pharma Inc $4,598.29 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363159
Principal investigator 1 Astellas Pharma Inc $3,640.71 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363161
Principal investigator 1 Astellas Pharma Inc $2,585.75 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363163
Principal investigator 1 Astellas Pharma Inc $3,607.04 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363165
Principal investigator 1 Astellas Pharma Inc $3,640.71 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363167
Principal investigator 1 Astellas Pharma Inc $2,214.58 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363169
Principal investigator 1 Astellas Pharma Inc $3,640.71 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363171
Principal investigator 1 Astellas Pharma Inc $3,607.04 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363173
Principal investigator 1 Astellas Pharma Inc $3,640.71 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363175
Principal investigator 1 Astellas Pharma Inc $2,922.59 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363177
Principal investigator 1 Astellas Pharma Inc $1,823.08 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363179
Principal investigator 1 Astellas Pharma Inc $1,489.63 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363181
Principal investigator 1 Astellas Pharma Inc $3,607.04 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363183
Principal investigator 1 Astellas Pharma Inc $1,823.08 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363185
Principal investigator 1 Astellas Pharma Inc $1,823.08 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363187
Principal investigator 1 Astellas Pharma Inc $3,640.71 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363189
Principal investigator 1 Astellas Pharma Inc $5,390.93 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363191
Principal investigator 1 Astellas Pharma Inc $4,061.91 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363193
Principal investigator 1 Astellas Pharma Inc $2,585.75 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363195
Principal investigator 1 Astellas Pharma Inc $4,091.43 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363197
Principal investigator 1 Astellas Pharma Inc $5,012.08 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363199
Principal investigator 1 Astellas Pharma Inc $3,607.04 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363201
Principal investigator 1 Astellas Pharma Inc $4,091.43 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363203
Principal investigator 1 Astellas Pharma Inc $4,091.43 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363205
Principal investigator 1 Astellas Pharma Inc $1,823.08 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363207
Principal investigator 1 Astellas Pharma Inc $1,823.08 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363209
Principal investigator 1 Astellas Pharma Inc $3,607.04 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363211
Principal investigator 1 Astellas Pharma Inc $3,607.04 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363213
Principal investigator 1 Astellas Pharma Inc $4,091.43 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363215
Principal investigator 1 Astellas Pharma Inc $3,607.04 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363217
Principal investigator 1 Astellas Pharma Inc $4,018.71 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363219
Principal investigator 1 Astellas Pharma Inc $4,061.91 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363221
Principal investigator 1 Astellas Pharma Inc $2,861.15 10/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363223
Principal investigator 1 Astellas Pharma Global Development $83,260.00 10/09/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma No dispute reported 06/30/2026 1234183803
Principal investigator 1 Astellas Pharma Inc $4,091.43 09/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363061
Principal investigator 1 Astellas Pharma Inc $4,091.43 09/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363083
Principal investigator 1 Astellas Pharma Global Development $2,324.00 09/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma No dispute reported 06/30/2026 1234183801
Principal investigator 1 Astellas Pharma Inc $1,489.63 09/03/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363059
Principal investigator 1 Astellas Pharma Inc $3,607.04 09/03/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363063
Principal investigator 1 Astellas Pharma Inc $4,091.43 09/03/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363065
Principal investigator 1 Astellas Pharma Inc $4,091.43 09/03/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363067
Principal investigator 1 Astellas Pharma Inc $4,091.43 09/03/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363069
Principal investigator 1 Astellas Pharma Inc $4,091.43 09/03/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363071
Principal investigator 1 Astellas Pharma Inc $2,861.15 09/03/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363073
Principal investigator 1 Astellas Pharma Inc $4,091.43 09/03/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363075
Principal investigator 1 Astellas Pharma Inc $4,091.43 09/03/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363077
Principal investigator 1 Astellas Pharma Inc $7,032.93 09/03/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363079
Principal investigator 1 Astellas Pharma Inc $4,061.91 09/03/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363081
Principal investigator 1 Astellas Pharma Inc $121.01 09/03/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363085
Principal investigator 1 Astellas Pharma Inc $121.01 09/03/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363087
Principal investigator 1 Astellas Pharma Inc $4,091.43 09/03/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363089
Principal investigator 1 Astellas Pharma Inc $121.01 09/03/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363091
Principal investigator 1 Astellas Pharma Inc $4,091.43 09/03/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363093
Principal investigator 1 Merck Sharp & Dohme LLC $749,604.64 08/20/2025 Non-covered Recipient Entity
Memorial Sloan Kettering CA Ctr
A Phase 2 Trial to Evaluate the Safety and Antitumor Activity of Pembrolizumab and OLApaRib (POLAR) for Individuals with Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency No dispute reported 06/30/2026 1232932047
Principal investigator 1 Astellas Pharma Global Development $6,152.96 07/31/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Open-label Study to Assess the Safety and Tolerability of Zolbetuximab (IMAB362) in Combination With Chemotherapy (mFOLFIRINOX) in Participants With CLDN18.2 Positive Metastatic Pancreatic Adenocarcinoma No dispute reported 06/30/2026 1234183561
Principal investigator 1 Astellas Pharma Global Development $3,014.02 07/31/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Open-label Study to Assess the Safety and Tolerability of Zolbetuximab (IMAB362) in Combination With Chemotherapy (mFOLFIRINOX) in Participants With CLDN18.2 Positive Metastatic Pancreatic Adenocarcinoma No dispute reported 06/30/2026 1234183563
Principal investigator 1 Astellas Pharma Global Development $19,352.03 07/31/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Open-label Study to Assess the Safety and Tolerability of Zolbetuximab (IMAB362) in Combination With Chemotherapy (mFOLFIRINOX) in Participants With CLDN18.2 Positive Metastatic Pancreatic Adenocarcinoma No dispute reported 06/30/2026 1234183565
Principal investigator 1 Astellas Pharma Global Development $2,781.00 07/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma No dispute reported 06/30/2026 1234183799
Principal investigator 1 Astellas Pharma Inc $5,390.93 07/28/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363031
Principal investigator 1 Astellas Pharma Inc $2,585.75 07/28/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363033
Principal investigator 1 Astellas Pharma Inc $7,032.93 07/28/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363035
Principal investigator 1 Astellas Pharma Inc $3,640.71 07/28/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363037
Principal investigator 1 Astellas Pharma Inc $4,018.71 07/28/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363039
Principal investigator 1 Astellas Pharma Inc $4,598.29 07/28/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363041
Principal investigator 1 Astellas Pharma Inc $3,640.71 07/28/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363043
Principal investigator 1 Astellas Pharma Inc $5,910.49 07/28/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363045
Principal investigator 1 Astellas Pharma Inc $4,061.91 07/28/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363047
Principal investigator 1 Astellas Pharma Inc $3,640.71 07/28/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363049
Principal investigator 1 Astellas Pharma Inc $4,018.71 07/28/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363051
Principal investigator 1 Astellas Pharma Inc $4,598.29 07/28/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363053
Principal investigator 1 Astellas Pharma Inc $4,061.91 07/28/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363055
Principal investigator 1 Astellas Pharma Inc $3,640.71 07/28/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363057
Principal investigator 1 Astellas Pharma Global Development $2,781.00 07/22/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma No dispute reported 06/30/2026 1234183797
Principal investigator 1 Astellas Pharma Inc $1,407.63 06/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363029
Principal investigator 1 Astellas Pharma Inc $3,647.54 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362449
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362455
Principal investigator 1 Astellas Pharma Inc $5,657.79 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362459
Principal investigator 1 Astellas Pharma Inc $1,512.96 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362463
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362465
Principal investigator 1 Astellas Pharma Inc $2,214.58 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362467
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362469
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362473
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362475
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362479
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362481
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362483
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362485
Principal investigator 1 Astellas Pharma Inc $5,657.79 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362491
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362493
Principal investigator 1 Astellas Pharma Inc $3,647.54 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362499
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362501
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362503
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362505
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362511
Principal investigator 1 Astellas Pharma Inc $3,647.54 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362515
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362517
Principal investigator 1 Astellas Pharma Inc $1,769.46 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362521
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362525
Principal investigator 1 Astellas Pharma Inc $2,986.42 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362527
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362529
Principal investigator 1 Astellas Pharma Inc $1,513.00 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362531
Principal investigator 1 Astellas Pharma Inc $1,512.96 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362533
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362535
Principal investigator 1 Astellas Pharma Inc $1,400.23 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362537
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362539
Principal investigator 1 Astellas Pharma Inc $5,657.79 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362541
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362543
Principal investigator 1 Astellas Pharma Inc $1,512.96 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362545
Principal investigator 1 Astellas Pharma Inc $1,769.46 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362551
Principal investigator 1 Astellas Pharma Inc $2,214.58 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362553
Principal investigator 1 Astellas Pharma Inc $5,012.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362555
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362557
Principal investigator 1 Astellas Pharma Inc $4,091.79 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362559
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362561
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362565
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362567
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362571
Principal investigator 1 Astellas Pharma Inc $1,512.96 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362573
Principal investigator 1 Astellas Pharma Inc $1,769.46 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362577
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362579
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362581
Principal investigator 1 Astellas Pharma Inc $2,214.58 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362585
Principal investigator 1 Astellas Pharma Inc $2,214.58 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362587
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362591
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362593
Principal investigator 1 Astellas Pharma Inc $1,489.63 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362595
Principal investigator 1 Astellas Pharma Inc $5,657.79 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362597
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362601
Principal investigator 1 Astellas Pharma Inc $5,046.23 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362605
Principal investigator 1 Astellas Pharma Inc $5,657.79 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362607
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362609
Principal investigator 1 Astellas Pharma Inc $3,647.54 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362611
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362615
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362621
Principal investigator 1 Astellas Pharma Inc $1,513.00 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362623
Principal investigator 1 Astellas Pharma Inc $2,986.42 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362629
Principal investigator 1 Astellas Pharma Inc $1,769.46 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362631
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362633
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362637
Principal investigator 1 Astellas Pharma Inc $1,513.00 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362643
Principal investigator 1 Astellas Pharma Inc $6,616.28 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362647
Principal investigator 1 Astellas Pharma Inc $1,302.36 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362651
Principal investigator 1 Astellas Pharma Inc $6,616.28 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362653
Principal investigator 1 Astellas Pharma Inc $4,091.79 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362655
Principal investigator 1 Astellas Pharma Inc $1,118.92 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362659
Principal investigator 1 Astellas Pharma Inc $2,214.58 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362661
Principal investigator 1 Astellas Pharma Inc $2,986.42 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362667
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362671
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362675
Principal investigator 1 Astellas Pharma Inc $2,214.58 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362677
Principal investigator 1 Astellas Pharma Inc $3,647.54 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362679
Principal investigator 1 Astellas Pharma Inc $1,769.46 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362681
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362683
Principal investigator 1 Astellas Pharma Inc $2,986.42 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362685
Principal investigator 1 Astellas Pharma Inc $6,616.28 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362689
Principal investigator 1 Astellas Pharma Inc $2,922.59 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362691
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362695
Principal investigator 1 Astellas Pharma Inc $3,647.54 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362697
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362699
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362701
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362703
Principal investigator 1 Astellas Pharma Inc $121.01 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362705
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362707
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362711
Principal investigator 1 Astellas Pharma Inc $3,647.54 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362713
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362715
Principal investigator 1 Astellas Pharma Inc $5,046.23 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362721
Principal investigator 1 Astellas Pharma Inc $2,922.59 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362723
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362725
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362727
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362729
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362731
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362733
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362739
Principal investigator 1 Astellas Pharma Inc $6,616.28 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362741
Principal investigator 1 Astellas Pharma Inc $2,986.42 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362745
Principal investigator 1 Astellas Pharma Inc $4,091.79 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362747
Principal investigator 1 Astellas Pharma Inc $121.01 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362749
Principal investigator 1 Astellas Pharma Inc $6,616.28 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362753
Principal investigator 1 Astellas Pharma Inc $3,647.54 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362755
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362757
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362759
Principal investigator 1 Astellas Pharma Inc $5,012.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362761
Principal investigator 1 Astellas Pharma Inc $1,400.23 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362769
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362773
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362775
Principal investigator 1 Astellas Pharma Inc $2,214.58 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362777
Principal investigator 1 Astellas Pharma Inc $3,647.54 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362785
Principal investigator 1 Astellas Pharma Inc $2,986.42 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362791
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362793
Principal investigator 1 Astellas Pharma Inc $1,513.00 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362797
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362799
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362801
Principal investigator 1 Astellas Pharma Inc $1,400.23 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362807
Principal investigator 1 Astellas Pharma Inc $5,012.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362809
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362817
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362819
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362823
Principal investigator 1 Astellas Pharma Inc $2,922.59 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362825
Principal investigator 1 Astellas Pharma Inc $1,769.46 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362829
Principal investigator 1 Astellas Pharma Inc $1,513.00 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362831
Principal investigator 1 Astellas Pharma Inc $5,657.79 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362835
Principal investigator 1 Astellas Pharma Inc $5,046.23 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362837
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362839
Principal investigator 1 Astellas Pharma Inc $3,647.54 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362841
Principal investigator 1 Astellas Pharma Inc $6,616.28 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362843
Principal investigator 1 Astellas Pharma Inc $2,986.42 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362845
Principal investigator 1 Astellas Pharma Inc $5,046.23 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362847
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362849
Principal investigator 1 Astellas Pharma Inc $1,513.00 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362851
Principal investigator 1 Astellas Pharma Inc $1,513.00 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362853
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362855
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362857
Principal investigator 1 Astellas Pharma Inc $1,769.46 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362861
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362865
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362867
Principal investigator 1 Astellas Pharma Inc $5,012.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362869
Principal investigator 1 Astellas Pharma Inc $1,513.00 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362873
Principal investigator 1 Astellas Pharma Inc $5,012.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362879
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362881
Principal investigator 1 Astellas Pharma Inc $5,012.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362883
Principal investigator 1 Astellas Pharma Inc $1,513.00 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362887
Principal investigator 1 Astellas Pharma Inc $3,647.54 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362889
Principal investigator 1 Astellas Pharma Inc $2,922.59 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362891
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362897
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362899
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362903
Principal investigator 1 Astellas Pharma Inc $5,657.79 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362913
Principal investigator 1 Astellas Pharma Inc $4,091.79 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362915
Principal investigator 1 Astellas Pharma Inc $6,616.28 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362919
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362921
Principal investigator 1 Astellas Pharma Inc $6,616.28 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362923
Principal investigator 1 Astellas Pharma Inc $5,657.79 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362925
Principal investigator 1 Astellas Pharma Inc $1,513.00 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362927
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362929
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362931
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362933
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362935
Principal investigator 1 Astellas Pharma Inc $1,512.96 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362937
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362939
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362945
Principal investigator 1 Astellas Pharma Inc $3,647.54 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362947
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362949
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362951
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362953
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362955
Principal investigator 1 Astellas Pharma Inc $3,647.54 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362959
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362961
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362965
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362973
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362977
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362981
Principal investigator 1 Astellas Pharma Inc $5,046.23 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362983
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362985
Principal investigator 1 Astellas Pharma Inc $4,091.79 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362987
Principal investigator 1 Astellas Pharma Inc $6,616.28 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362989
Principal investigator 1 Astellas Pharma Inc $3,647.54 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362991
Principal investigator 1 Astellas Pharma Inc $5,012.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362993
Principal investigator 1 Astellas Pharma Inc $1,823.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362995
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362997
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362999
Principal investigator 1 Astellas Pharma Inc $4,091.79 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363003
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363005
Principal investigator 1 Astellas Pharma Inc $2,986.42 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363007
Principal investigator 1 Astellas Pharma Inc $1,302.36 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363009
Principal investigator 1 Astellas Pharma Inc $5,012.08 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363013
Principal investigator 1 Astellas Pharma Inc $1,769.46 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363015
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363019
Principal investigator 1 Astellas Pharma Inc $3,607.04 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363021
Principal investigator 1 Astellas Pharma Inc $3,640.71 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363023
Principal investigator 1 Astellas Pharma Inc $4,091.43 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363025
Principal investigator 1 Astellas Pharma Inc $3,647.54 05/29/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363027
Principal investigator 1 Astellas Pharma Inc $893.70 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362451
Principal investigator 1 Astellas Pharma Inc $745.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362453
Principal investigator 1 Astellas Pharma Inc $528.26 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362457
Principal investigator 1 Astellas Pharma Inc $4,148.55 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362461
Principal investigator 1 Astellas Pharma Inc $446.85 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362471
Principal investigator 1 Astellas Pharma Inc $446.85 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362477
Principal investigator 1 Astellas Pharma Inc $298.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362487
Principal investigator 1 Astellas Pharma Inc $446.85 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362489
Principal investigator 1 Astellas Pharma Inc $1,787.40 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362495
Principal investigator 1 Astellas Pharma Inc $149.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362497
Principal investigator 1 Astellas Pharma Inc $4,598.29 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362507
Principal investigator 1 Astellas Pharma Inc $3,127.95 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362509
Principal investigator 1 Astellas Pharma Inc $893.70 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362513
Principal investigator 1 Astellas Pharma Inc $446.85 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362519
Principal investigator 1 Astellas Pharma Inc $810.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362523
Principal investigator 1 Astellas Pharma Inc $298.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362547
Principal investigator 1 Astellas Pharma Inc $446.85 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362549
Principal investigator 1 Astellas Pharma Inc $810.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362563
Principal investigator 1 Astellas Pharma Inc $3,640.71 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362569
Principal investigator 1 Astellas Pharma Inc $596.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362575
Principal investigator 1 Astellas Pharma Inc $298.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362583
Principal investigator 1 Astellas Pharma Inc $2,000.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362589
Principal investigator 1 Astellas Pharma Inc $1,061.45 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362599
Principal investigator 1 Astellas Pharma Inc $1,620.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362603
Principal investigator 1 Astellas Pharma Inc $893.70 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362613
Principal investigator 1 Astellas Pharma Inc $810.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362617
Principal investigator 1 Astellas Pharma Inc $149.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362619
Principal investigator 1 Astellas Pharma Inc $4,018.71 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362625
Principal investigator 1 Astellas Pharma Inc $4,598.29 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362627
Principal investigator 1 Astellas Pharma Inc $893.70 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362635
Principal investigator 1 Astellas Pharma Inc $149.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362639
Principal investigator 1 Astellas Pharma Inc $810.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362641
Principal investigator 1 Astellas Pharma Inc $2,606.50 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362645
Principal investigator 1 Astellas Pharma Inc $298.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362649
Principal investigator 1 Astellas Pharma Inc $298.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362657
Principal investigator 1 Astellas Pharma Inc $1,043.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362663
Principal investigator 1 Astellas Pharma Inc $149.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362665
Principal investigator 1 Astellas Pharma Inc $810.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362669
Principal investigator 1 Astellas Pharma Inc $149.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362673
Principal investigator 1 Astellas Pharma Inc $446.85 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362687
Principal investigator 1 Astellas Pharma Inc $446.85 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362693
Principal investigator 1 Astellas Pharma Inc $149.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362709
Principal investigator 1 Astellas Pharma Inc $298.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362717
Principal investigator 1 Astellas Pharma Inc $3,640.71 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362719
Principal investigator 1 Astellas Pharma Inc $149.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362735
Principal investigator 1 Astellas Pharma Inc $810.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362737
Principal investigator 1 Astellas Pharma Inc $1,620.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362743
Principal investigator 1 Astellas Pharma Inc $2,234.25 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362751
Principal investigator 1 Astellas Pharma Inc $528.26 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362763
Principal investigator 1 Astellas Pharma Inc $745.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362765
Principal investigator 1 Astellas Pharma Inc $1,340.55 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362767
Principal investigator 1 Astellas Pharma Inc $3,640.71 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362771
Principal investigator 1 Astellas Pharma Inc $447.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362779
Principal investigator 1 Astellas Pharma Inc $446.85 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362781
Principal investigator 1 Astellas Pharma Inc $447.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362783
Principal investigator 1 Astellas Pharma Inc $810.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362787
Principal investigator 1 Astellas Pharma Inc $1,340.55 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362789
Principal investigator 1 Astellas Pharma Inc $149.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362795
Principal investigator 1 Astellas Pharma Inc $893.70 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362803
Principal investigator 1 Astellas Pharma Inc $1,340.55 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362805
Principal investigator 1 Astellas Pharma Inc $149.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362811
Principal investigator 1 Astellas Pharma Inc $893.70 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362813
Principal investigator 1 Astellas Pharma Inc $1,061.45 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362815
Principal investigator 1 Astellas Pharma Inc $149.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362821
Principal investigator 1 Astellas Pharma Inc $149.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362827
Principal investigator 1 Astellas Pharma Inc $1,061.45 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362833
Principal investigator 1 Astellas Pharma Inc $446.85 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362859
Principal investigator 1 Astellas Pharma Inc $2,234.25 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362863
Principal investigator 1 Astellas Pharma Inc $745.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362871
Principal investigator 1 Astellas Pharma Inc $1,620.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362875
Principal investigator 1 Astellas Pharma Inc $446.85 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362877
Principal investigator 1 Astellas Pharma Inc $810.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362885
Principal investigator 1 Astellas Pharma Inc $528.26 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362893
Principal investigator 1 Astellas Pharma Inc $2,234.25 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362895
Principal investigator 1 Astellas Pharma Inc $528.26 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362901
Principal investigator 1 Astellas Pharma Inc $149.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362905
Principal investigator 1 Astellas Pharma Inc $1,061.45 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362907
Principal investigator 1 Astellas Pharma Inc $1,136.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362909
Principal investigator 1 Astellas Pharma Inc $149.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362911
Principal investigator 1 Astellas Pharma Inc $446.85 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362917
Principal investigator 1 Astellas Pharma Inc $3,640.71 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362941
Principal investigator 1 Astellas Pharma Inc $1,787.40 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362943
Principal investigator 1 Astellas Pharma Inc $149.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362957
Principal investigator 1 Astellas Pharma Inc $4,018.71 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362963
Principal investigator 1 Astellas Pharma Inc $149.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362967
Principal investigator 1 Astellas Pharma Inc $810.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362969
Principal investigator 1 Astellas Pharma Inc $596.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362971
Principal investigator 1 Astellas Pharma Inc $446.85 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362975
Principal investigator 1 Astellas Pharma Inc $447.00 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362979
Principal investigator 1 Astellas Pharma Inc $446.85 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363001
Principal investigator 1 Astellas Pharma Inc $893.70 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363011
Principal investigator 1 Astellas Pharma Inc $446.85 05/26/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225363017
Principal investigator 1 Astellas Pharma Inc $3,640.71 04/24/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362383
Principal investigator 1 Astellas Pharma Inc $4,061.91 04/24/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362385
Principal investigator 1 Astellas Pharma Inc $4,598.29 04/24/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362387
Principal investigator 1 Astellas Pharma Inc $4,018.71 04/24/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362389
Principal investigator 1 Astellas Pharma Inc $4,061.91 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362167
Principal investigator 1 Astellas Pharma Inc $4,061.91 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362169
Principal investigator 1 Astellas Pharma Inc $6,273.64 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362243
Principal investigator 1 Astellas Pharma Inc $3,640.71 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362247
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362249
Principal investigator 1 Astellas Pharma Inc $2,861.15 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362253
Principal investigator 1 Astellas Pharma Inc $4,598.29 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362259
Principal investigator 1 Astellas Pharma Inc $5,651.48 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362261
Principal investigator 1 Astellas Pharma Inc $4,061.91 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362263
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362265
Principal investigator 1 Astellas Pharma Inc $3,640.71 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362267
Principal investigator 1 Astellas Pharma Inc $3,607.04 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362269
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362271
Principal investigator 1 Astellas Pharma Inc $4,018.71 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362273
Principal investigator 1 Astellas Pharma Inc $3,647.54 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362275
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362277
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362279
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362281
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362283
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362285
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362287
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362289
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362291
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362293
Principal investigator 1 Astellas Pharma Inc $4,061.91 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362295
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362297
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362299
Principal investigator 1 Astellas Pharma Inc $5,046.23 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362301
Principal investigator 1 Astellas Pharma Inc $5,390.93 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362303
Principal investigator 1 Astellas Pharma Inc $2,861.15 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362305
Principal investigator 1 Astellas Pharma Inc $4,018.71 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362307
Principal investigator 1 Astellas Pharma Inc $3,640.71 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362309
Principal investigator 1 Astellas Pharma Inc $3,640.71 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362311
Principal investigator 1 Astellas Pharma Inc $3,640.71 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362313
Principal investigator 1 Astellas Pharma Inc $4,061.91 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362315
Principal investigator 1 Astellas Pharma Inc $4,598.29 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362317
Principal investigator 1 Astellas Pharma Inc $3,640.71 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362319
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362321
Principal investigator 1 Astellas Pharma Inc $4,061.91 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362323
Principal investigator 1 Astellas Pharma Inc $4,061.91 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362325
Principal investigator 1 Astellas Pharma Inc $7,396.08 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362327
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362329
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362331
Principal investigator 1 Astellas Pharma Inc $4,061.91 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362333
Principal investigator 1 Astellas Pharma Inc $5,910.49 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362335
Principal investigator 1 Astellas Pharma Inc $524.72 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362337
Principal investigator 1 Astellas Pharma Inc $3,640.71 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362339
Principal investigator 1 Astellas Pharma Inc $2,585.75 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362341
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362343
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362345
Principal investigator 1 Astellas Pharma Inc $3,640.71 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362347
Principal investigator 1 Astellas Pharma Inc $7,032.93 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362349
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362351
Principal investigator 1 Astellas Pharma Inc $5,390.93 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362353
Principal investigator 1 Astellas Pharma Inc $3,640.71 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362355
Principal investigator 1 Astellas Pharma Inc $4,018.71 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362357
Principal investigator 1 Astellas Pharma Inc $4,598.29 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362359
Principal investigator 1 Astellas Pharma Inc $3,640.71 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362361
Principal investigator 1 Astellas Pharma Inc $3,640.71 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362363
Principal investigator 1 Astellas Pharma Inc $3,640.71 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362365
Principal investigator 1 Astellas Pharma Inc $4,598.29 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362367
Principal investigator 1 Astellas Pharma Inc $3,640.71 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362369
Principal investigator 1 Astellas Pharma Inc $2,585.75 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362371
Principal investigator 1 Astellas Pharma Inc $5,910.49 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362373
Principal investigator 1 Astellas Pharma Inc $2,861.15 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362375
Principal investigator 1 Astellas Pharma Inc $4,018.71 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362377
Principal investigator 1 Astellas Pharma Inc $7,032.93 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362379
Principal investigator 1 Astellas Pharma Inc $4,061.91 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362381
Principal investigator 1 Astellas Pharma Inc $4,598.29 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362393
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362395
Principal investigator 1 Astellas Pharma Inc $2,628.95 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362397
Principal investigator 1 Astellas Pharma Inc $3,640.71 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362401
Principal investigator 1 Astellas Pharma Inc $4,598.29 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362405
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362413
Principal investigator 1 Astellas Pharma Inc $4,061.91 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362417
Principal investigator 1 Astellas Pharma Inc $3,640.71 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362421
Principal investigator 1 Astellas Pharma Inc $4,061.91 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362423
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362425
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362427
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362431
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362433
Principal investigator 1 Astellas Pharma Inc $5,012.08 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362439
Principal investigator 1 Astellas Pharma Inc $3,640.71 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362441
Principal investigator 1 Astellas Pharma Inc $5,720.73 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362443
Principal investigator 1 Astellas Pharma Inc $121.01 04/18/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362447
Principal investigator 1 Astellas Pharma Inc $2,214.58 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362171
Principal investigator 1 Astellas Pharma Inc $5,657.79 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362173
Principal investigator 1 Astellas Pharma Inc $3,647.54 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362175
Principal investigator 1 Astellas Pharma Inc $5,657.79 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362177
Principal investigator 1 Astellas Pharma Inc $3,647.54 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362179
Principal investigator 1 Astellas Pharma Inc $1,512.96 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362181
Principal investigator 1 Astellas Pharma Inc $3,647.54 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362183
Principal investigator 1 Astellas Pharma Inc $2,922.59 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362185
Principal investigator 1 Astellas Pharma Inc $6,616.28 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362187
Principal investigator 1 Astellas Pharma Inc $2,986.42 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362189
Principal investigator 1 Astellas Pharma Inc $5,046.23 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362191
Principal investigator 1 Astellas Pharma Inc $1,769.46 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362193
Principal investigator 1 Astellas Pharma Inc $3,647.54 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362195
Principal investigator 1 Astellas Pharma Inc $1,823.08 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362197
Principal investigator 1 Astellas Pharma Inc $1,823.08 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362199
Principal investigator 1 Astellas Pharma Inc $2,986.42 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362201
Principal investigator 1 Astellas Pharma Inc $3,607.04 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362203
Principal investigator 1 Astellas Pharma Inc $5,012.08 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362205
Principal investigator 1 Astellas Pharma Inc $6,616.28 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362207
Principal investigator 1 Astellas Pharma Inc $4,091.79 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362209
Principal investigator 1 Astellas Pharma Inc $6,481.28 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362211
Principal investigator 1 Astellas Pharma Inc $1,607.46 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362213
Principal investigator 1 Astellas Pharma Inc $4,091.43 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362215
Principal investigator 1 Astellas Pharma Inc $5,046.23 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362217
Principal investigator 1 Astellas Pharma Inc $2,214.58 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362219
Principal investigator 1 Astellas Pharma Inc $6,481.28 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362221
Principal investigator 1 Astellas Pharma Inc $5,657.79 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362223
Principal investigator 1 Astellas Pharma Inc $3,647.54 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362225
Principal investigator 1 Astellas Pharma Inc $1,823.08 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362227
Principal investigator 1 Astellas Pharma Inc $5,046.23 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362229
Principal investigator 1 Astellas Pharma Inc $2,214.58 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362231
Principal investigator 1 Astellas Pharma Inc $2,922.59 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362233
Principal investigator 1 Astellas Pharma Inc $1,823.08 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362235
Principal investigator 1 Astellas Pharma Inc $5,046.23 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362237
Principal investigator 1 Astellas Pharma Inc $4,091.43 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362239
Principal investigator 1 Astellas Pharma Inc $1,513.00 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362241
Principal investigator 1 Astellas Pharma Inc $3,647.54 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362245
Principal investigator 1 Astellas Pharma Inc $1,513.00 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362251
Principal investigator 1 Astellas Pharma Inc $5,657.79 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362255
Principal investigator 1 Astellas Pharma Inc $6,481.28 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362257
Principal investigator 1 Astellas Pharma Inc $3,607.04 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362391
Principal investigator 1 Astellas Pharma Inc $5,012.08 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362399
Principal investigator 1 Astellas Pharma Inc $3,647.54 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362403
Principal investigator 1 Astellas Pharma Inc $1,512.96 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362407
Principal investigator 1 Astellas Pharma Inc $2,214.58 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362409
Principal investigator 1 Astellas Pharma Inc $4,091.43 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362411
Principal investigator 1 Astellas Pharma Inc $1,607.46 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362415
Principal investigator 1 Astellas Pharma Inc $3,647.54 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362419
Principal investigator 1 Astellas Pharma Inc $5,012.08 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362429
Principal investigator 1 Astellas Pharma Inc $1,607.46 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362435
Principal investigator 1 Astellas Pharma Inc $3,647.54 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362437
Principal investigator 1 Astellas Pharma Inc $1,513.00 04/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362445
Principal investigator 1 Astellas Pharma Global Development $5,815.80 02/13/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma No dispute reported 06/30/2026 1234183795
Principal investigator 1 Astellas Pharma Inc $5,001.75 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362079
Principal investigator 1 Astellas Pharma Inc $810.00 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362081
Principal investigator 1 Astellas Pharma Inc $1,620.00 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362083
Principal investigator 1 Astellas Pharma Inc $10,003.50 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362085
Principal investigator 1 Astellas Pharma Inc $10,003.50 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362087
Principal investigator 1 Astellas Pharma Inc $1,620.00 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362089
Principal investigator 1 Astellas Pharma Inc $10,003.50 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362091
Principal investigator 1 Astellas Pharma Inc $10,003.50 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362093
Principal investigator 1 Astellas Pharma Inc $2,430.00 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362095
Principal investigator 1 Astellas Pharma Inc $1,620.00 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362097
Principal investigator 1 Astellas Pharma Inc $10,003.50 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362099
Principal investigator 1 Astellas Pharma Inc $10,003.50 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362101
Principal investigator 1 Astellas Pharma Inc $1,620.00 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362103
Principal investigator 1 Astellas Pharma Inc $10,003.50 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362105
Principal investigator 1 Astellas Pharma Inc $1,620.00 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362107
Principal investigator 1 Astellas Pharma Inc $5,001.75 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362109
Principal investigator 1 Astellas Pharma Inc $1,620.00 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362111
Principal investigator 1 Astellas Pharma Inc $10,003.50 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362113
Principal investigator 1 Astellas Pharma Inc $10,003.50 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362115
Principal investigator 1 Astellas Pharma Inc $1,620.00 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362117
Principal investigator 1 Astellas Pharma Inc $10,003.50 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362119
Principal investigator 1 Astellas Pharma Inc $10,003.50 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362121
Principal investigator 1 Astellas Pharma Inc $5,001.75 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362123
Principal investigator 1 Astellas Pharma Inc $5,001.75 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362125
Principal investigator 1 Astellas Pharma Inc $10,003.50 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362127
Principal investigator 1 Astellas Pharma Inc $1,620.00 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362129
Principal investigator 1 Astellas Pharma Inc $5,001.75 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362131
Principal investigator 1 Astellas Pharma Inc $15,005.25 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362133
Principal investigator 1 Astellas Pharma Inc $10,003.50 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362135
Principal investigator 1 Astellas Pharma Inc $810.00 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362137
Principal investigator 1 Astellas Pharma Inc $10,003.50 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362139
Principal investigator 1 Astellas Pharma Inc $5,001.75 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362141
Principal investigator 1 Astellas Pharma Inc $10,003.50 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362143
Principal investigator 1 Astellas Pharma Inc $1,620.00 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362145
Principal investigator 1 Astellas Pharma Inc $810.00 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362147
Principal investigator 1 Astellas Pharma Inc $10,003.50 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362149
Principal investigator 1 Astellas Pharma Inc $10,003.50 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362151
Principal investigator 1 Astellas Pharma Inc $1,620.00 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362153
Principal investigator 1 Astellas Pharma Inc $10,003.50 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362155
Principal investigator 1 Astellas Pharma Inc $5,001.75 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362157
Principal investigator 1 Astellas Pharma Inc $5,001.75 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362159
Principal investigator 1 Astellas Pharma Inc $1,620.00 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362161
Principal investigator 1 Astellas Pharma Inc $1,620.00 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362163
Principal investigator 1 Astellas Pharma Inc $1,620.00 01/17/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225362165
Principal investigator 1 Astellas Pharma Global Development $13,198.00 01/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma No dispute reported 06/30/2026 1234183789
Principal investigator 1 Astellas Pharma Global Development $48,705.00 01/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma No dispute reported 06/30/2026 1234183791
Principal investigator 1 Astellas Pharma Global Development $90,314.00 01/16/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma No dispute reported 06/30/2026 1234183793
Principal investigator 1 Amgen Inc. $256,763.53 01/07/2025 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors No dispute reported 06/30/2026 1246644470